A group of aging and Alzheimer’s advocates will be meeting this week with the senior leadership of the National Institutes of Health (NIH) to call for an increase in funding for the National Institute on Aging (NIA). In advance of this meeting, the group has orchestrated a sign-on letter to demonstrate widespread support for $1.4 billion, an increase of $300 million, in the FY 2013 NIH Budget to support the NIA. A similar letter was generated last year and garnered more than 400 signatures.
Many of you may still have this phrase ringing in your ears if you traveled with children for any length of time this past holiday season. Representatives from the ACT-AD Coalition, chaired by the Alliance for Aging Research, heard these same words almost two years ago, not uttered from the mouths of babes, but rather by prominent officials at the Food and Drug Administration (FDA) in a conversation regarding evidence to support the use of biomarkers for Alzheimer’s disease in clinical trials for “disease-modifying” therapies.
The Alliance for Aging Research has added new members to its Science Advisory Board including a prominent bioethicist, a world-renowned neurologist, a Nobel Prize winner in economics, a leading longevity researcher, and the only cardiologist to receive all four major cardiovascular research awards.
Alzheimer’s is the only top 10 killer disease in the U.S. that cannot be prevented, cured or even treated effectively over time. One big barrier: there are not enough volunteers for experimental drug trials for Alzheimer’s disease.
This is one of the best articles on Alzheimer's I’ve seen to date. It is written by Don C. Reed, a stem cell activist in California, on the promise of current research, and on embryonic stem cells; bringing attention to a subject that is often forgotten and underfunded.